EVM
RDHL

Eaton Vance Management’s Redhill Biopharma RDHL Stock Holding History

Eaton Vance Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$20K Hold
40
– – ﹤0.01% 1534
2022
Q2 		$35K Hold
40
– – ﹤0.01% 1557
2022
Q1 		$102K Buy
40
+2
+5% +$4.74K ﹤0.01% 1786
2021
Q4 		$99K Hold
38
– – ﹤0.01% 1838
2021
Q3 		$176K Buy
+38
New +$258K ﹤0.01% 1350

Other funds holding RDHL

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $62.3B AUM 44.64% 1-Year Est. Return

Eaton Vance Management's RDHL Position: Q3 2022 in Review

Eaton Vance Management held its Redhill Biopharma (RDHL) position steady in Q3 2022 at 40 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #1534.

Eaton Vance Management first reported a position in RDHL in Q3 2021 and has held it in 5 quarters since. The position peaked at $176K in Q3 2021. 40 funds tracked by Wall St. Rank hold RDHL as of Q3 2022.

  • Eaton Vance Management held 40 shares of Redhill Biopharma worth $20K as of Q3 2022.
  • Eaton Vance Management left its Redhill Biopharma share count unchanged in Q3 2022.
  • Redhill Biopharma made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1534 holding.
  • Eaton Vance Management first reported a position in Redhill Biopharma in Q3 2021 and has held it in 5 quarters since.
  • Eaton Vance Management's Redhill Biopharma position peaked at $176K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.